23andMe announced the creation of a new therapeutics group and appointment of Richard Scheller, Ph.D. as chief science officer and head of therapeutics to lead it. Dr. Scheller retired in December 2014 from a distinguished 14 year career as an executive at Genentech where he was the executive vice president of research and early development. When Dr. Scheller assumes his post at the beginning of April 2015 as 23andMe's chief science officer and head of therapeutics, he will help build a dedicated research and development team.

Dr. Scheller is a member of the American Academy of Arts & Sciences and the National Academy of Sciences. He also currently serves on the Board of Trustees for the California Institute of Technology.